Cognitive and neurological research peptides target distinct brain pathways — BDNF signaling, neurogenesis, HGF/MET receptor activation, serotonergic modulation, and hypothalamic-pituitary circuits. Here is a mechanism-grounded guide to the most-studied cognitive research peptides.
Selank is a synthetic heptapeptide analogue of tuftsin, developed in Russia. Research has examined it primarily for anxiolytic effects in rodent models — studies show it modulates GABAergic transmission without the dependence liabilities of benzodiazepines in animal models. It is often studied alongside Semax for complementary cognitive research applications.
Semax is a synthetic heptapeptide analogue of ACTH 4-10 with a Pro-Gly-Pro stabilizing C-terminal addition. Russian research has examined it since the 1980s primarily for attention, memory, and neuroprotection in stroke models. Unlike native ACTH, Semax does not engage steroidogenic pathways — the ACTH 4-10 fragment is the neuropeptide portion without corticotropic activity.
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptide derived from angiotensin IV research. It engages the hepatocyte growth factor / MET receptor system. Preclinical research (Harding, Wright et al.) has examined its effects on synaptogenesis and memory in rodent models, with reports of substantially enhanced dendritic spine formation.
PE-22-28 is a synthetic peptide derived from spadin, which inhibits the TREK-1 (two-pore-domain K+) channel. Research has examined TREK-1 as a non-classical target in depression models — TREK-1 knockout mice show antidepressant-like behavioral phenotypes, suggesting blockade may produce similar effects without engaging monoamine pathways.
BDNF is a key neurotrophin regulating neuronal survival, growth, and synaptic plasticity. Recombinant BDNF is studied directly in preclinical neuroplasticity research, though delivery challenges (blood-brain barrier, short half-life) are significant. Many cognitive peptides (Semax, Selank) are studied because they upregulate endogenous BDNF.
Tesofensine is a serotonin-norepinephrine-dopamine reuptake inhibitor originally investigated in Parkinson's and Alzheimer's research, later studied for obesity. In cognitive research contexts, the triple-monoamine engagement has been examined for attention and motivation pathways in rodent models.
P21 is a peptide studied in adult hippocampal neurogenesis research. It engages pathways associated with neural precursor cell proliferation in the dentate gyrus. Research is earlier-stage than more-established cognitive peptides, with literature primarily in rodent models.
The Russian-research classic pairing. Selank for anxiolytic/GABAergic, Semax for attention/BDNF. Non-overlapping mechanisms covering anxiety and cognitive performance angles simultaneously.
Synaptogenesis focus. Dihexa engages HGF/MET; BDNF engages TrkB. Both upstream of synaptic plasticity but through distinct receptors — complementary in preclinical neuroplasticity research.
SMART MD's pre-dosed Brain Blend combines Dihexa (10mg) + Tesofensine (250mcg) + BPC-157 (125mcg) per tablet, x60 tablets. $287.98 — engineered for cognitive research protocols.
Emerging stack pairing non-monoaminergic (PE-22-28/TREK-1) with monoaminergic-modulating (Semax) mechanisms. Used in mood + cognition research models.
Semax has the largest Russian research literature base specifically on memory and attention paradigms. Dihexa has generated significant attention in Western literature for its reported synaptogenic effects on dendritic spines. For BDNF-pathway research, Semax upregulates endogenous BDNF; direct BDNF peptide is also studied but BBB delivery is a research challenge.
Selank modulates GABAergic transmission without classical benzodiazepine receptor binding. In rodent anxiolytic screening models (elevated plus maze, open field), Selank produces anxiolytic-like behavior without the dependence or tolerance characteristics of benzodiazepines in the same models. It is classified research-use-only; these findings do not apply to human medical use.
Routes vary by peptide and BBB penetration. Semax and Selank are often administered intranasally in preclinical protocols (the nasal epithelium provides a BBB-adjacent pathway). Dihexa is unusual in being orally active. BDNF and larger peptides are typically administered via direct CNS routes in research animals due to BBB limitations. Researchers should consult the primary literature for their specific protocol.
Yes. All cognitive research peptides listed here are legal to acquire for research purposes in the United States. They are classified as research-use-only compounds — not intended for human consumption in this form. Licensed researchers and physicians may acquire them for preclinical research protocols and practice-of-medicine use.
The blood-brain barrier (BBB) is a selective endothelial barrier that restricts which molecules enter CNS tissue from circulation. Peptides typically cross poorly due to size and charge. This affects route-of-administration choices in preclinical research — intranasal delivery, direct CNS injection, and molecular design (e.g., Dihexa's lipophilic modifications) are strategies researchers use to achieve CNS exposure in animal models.
Every SMART MD batch is verified by three independent U.S. laboratories — HPLC purity analysis, mass spectrometry, and LAL endotoxin testing. Lot-specific COAs are publicly verifiable at smartmdpeptides.com/verify before purchase.
Every cognitive research peptide in our catalog carries a 3-lab COA. Check it before you order.